Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
A Breakthrough Therapy Developed for Investigational Prenatal Treatment ER-004 a Rare Genetic Condition
ER-004, a breakthrough therapy for the prenatal treatment of XLHED, a life-threatening rare genetic condition was developed by EspeRare.
Gvoke HypoPen™ First Autoinjector Discovered for Severe Hypoglycemia
Xeris Pharmaceuticals, Inc discovered novel Gvoke HypoPen™ (glucagon injection),which is used for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above.
GIMOTI™, Novel Nasal Spray Developed for Treatment of Gastroparesisin Adults
GIMOTI™ (metoclopramide), novel nasal spray developed by Evoke Pharma, Inc specifically for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Crysvita - A Breakthrough Therapy Developed For Treatment of TumorInduced Osteomalacia TIO
Crysvita (burosumab-twza) injection the first therapy discovered for the treatment of patients with rare disease, tumor-induced osteomalacia (TIO) corresponding to the age two and older.
Eli Lilly and Company Launched New Rapid Acting Insulin Lyumjev™
Lyumjev™, a new and innovative rapid acting insulin ranging from 100 units/mL and 200 units/mL was launched by Eli Lilly and Company to enhance glycemic control in diabetic patients of type 1 & 2.
A Novel Oral Therapy Discovered to Treat Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
Insmed discovered Brensocatib for the treatment of adult patients with Non-cystic Fibrosis Bronchiectasis (NCFBE) for reducing exacerbations. Brensocatib is a novel oral, reversible inhibitor of Dipeptidyl Peptidase 1 (DPP1) for the treatment of bronchiectasis and other inflammatory diseases.
Retevmo™, The First Therapy Developed for Patients with Advanced RET-Driven Lung and Thyroid Cancers
Eli Lilly and Company discovered Retevmo™ (selpercatinib, 40 mg & 80 mg capsules) to treat patients with different types of cancers such as non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancer.
SUNOVION Launches KYNMOBI™ for the Treatment of Parkinson's Disease Off Episodes
Sunovion Pharmaceuticals Inc launched a novel drug KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) for the acute and intermittent treatment of off episodes in patients with Parkinson’s disease.
Archer, Inc Launches Next-Generation Sequencing (NGS) Device to Identify NTRK Gene Fusions in Cancer
ArcherDX, Inc has discovered a new next-generation sequencing (NGS) device to detect Neurotrophic Receptor Tyrosine Kinase (NTRK) gene fusions that leads to the formation and growth of cancer.
Deciphera Pharmaceuticals’ Develops QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumors in Adults
Deciphera Pharmaceuticals developed QINLOCK™ (ripretinib) 50mg capsules to treat adult patients with advanced gastrointestinal stromal tumour (GIST) who underwent prior treatment with three or more kinase inhibitors, including imatinib.
